U.S. Industrials Stock News

If you are wondering whether Ally Financial at around US$42.57 represents fair value or a potential opportunity, this article explains what the recent share price moves may indicate about the price you are paying. The stock has returned 5.7% over the last week and 17.8% over the last month. The 1 year return is 36.0%, while the year to date return reflects a 7.0% decline. Recent coverage of Ally Financial has focused on how its share price performance compares with the broader Consumer...

Over the last 7 days, the United States market has risen by 4.4%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% annually. While penny stocks might seem like a relic from earlier market times, they continue to represent smaller or less-established companies that can offer significant value when chosen wisely. By focusing on those with strong financials and clear growth potential, investors can uncover opportunities in these niche stocks that may...

The United States market has shown impressive momentum, climbing 4.4% in the last week and rising 32% over the past year, with earnings projected to grow by 16% annually in the coming years. In this dynamic environment, identifying stocks with strong fundamentals and growth potential can uncover promising opportunities for investors seeking to capitalize on these positive trends.

Context for General Electric’s Recent Share Performance General Electric (GE) has drawn fresh attention after recent share price moves, with the stock up about 2% over the past day, 10% over the past week, and 6% over the past month. Investors are reassessing what the current valuation implies for a business generating US$45.9b in revenue and US$8.6b in net income. See our latest analysis for General Electric. Recent trading suggests momentum has been choppy rather than one way, with short...

Ondas (ONDS) is back in focus after a cluster of contract wins tied to military engineering vehicles, airspace security for the 2026 FIFA World Cup, and a large-scale demining program, alongside a new European drone defense venture. See our latest analysis for Ondas. Despite the flurry of contract announcements, Ondas' recent share price return has been weak. The 30 day share price return is 7.48%, and the 90 day share price return is a 30.68% decline, while the 1 year total shareholder...

Putting W. P. Carey in context for income focused investors W. P. Carey (WPC) sits in the net lease REIT space with a portfolio of 1,682 single tenant properties and US$1.7b in annual revenue, drawing from industrial, warehouse, retail and investment management activities. For investors watching long term performance, WPC shows a total return of 25.0% over the past year and 32.4% over five years, with a year to date total return of 10.4% as of the latest close. See our latest analysis for W...

Wondering whether Selective Insurance Group at around US$80.90 is starting to look interesting on value, or still has more risk than reward baked into the price. The stock is up 2.1% over the last week and 5.9% over the last month, although year to date it shows a 3.1% decline and the 1 year return sits at a 6.5% loss, with a 3 year return of 11.4% loss and a 5 year return of 14.4% gain. Recent coverage has focused on the share price performance and how it compares with the wider insurance...

With no single headline event moving Diamondback Energy (FANG) today, investors are instead weighing its recent share performance, current valuation metrics, and the scale of its Permian focused oil and gas business. See our latest analysis for Diamondback Energy. At a share price of US$186.51, Diamondback’s 90 day share price return of 23.66% and year to date share price return of 22.43% contrast with a 1 year total shareholder return of 47.14%, suggesting momentum has been building over...

Acadia Pharmaceuticals has now made DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide for oral solution, broadly available in the US for treating Rett syndrome in adults and children aged two and older, following its FDA approval in December 2025 and confirmation of bioequivalence to the original DAYBUE oral solution. The launch not only offers caregivers greater flexibility in dose volume and taste, but also comes as Rett experts increasingly view trofinetide as...

If you are wondering whether Copa Holdings at around US$120.90 still offers value or if the easier gains have already been realized, this breakdown can help you frame what the current share price might be implying. The stock returned 8.4% over the last week, 9.5% over the last month, is roughly flat year to date with a 0.8% decline, and sits on a 42.6% return over the last year. This provides useful context before comparing price to fundamentals. Recent coverage has focused on Copa Holdings...

Wondering if Labcorp Holdings at around US$268.87 is still good value or starting to look fully priced, especially after a strong run? This article breaks that question down in plain terms. The stock has recently posted a 6.8% return year to date and 20.2% over the last year, with shorter term moves of 1.9% over 30 days and a slight 0.1% decline over 7 days that may have caught your attention. Recent news coverage has focused on Labcorp's position within the broader healthcare sector,...

Event driven snapshot of GE HealthCare Technologies stock GE HealthCare Technologies (GEHC) has been drawing attention after recent share price moves, with the stock up about 7.1% over the past week and 5.5% over the past month, while showing a 12.5% decline over the past 3 months. See our latest analysis for GE HealthCare Technologies. At a share price of $74.67, GE HealthCare Technologies has seen short term momentum soften compared with earlier weakness, with a 1 year total shareholder...

If you are wondering whether HP at around US$18.99 is a bargain or a value trap, the key is to understand what the current share price actually reflects about the business. Over the past week the stock is up 2.0%, while the 30 day return sits near 0.3%, set against a year to date return of about 14.2% decline and a 16.0% decline over the last year. These price moves sit against a backdrop where HP continues to attract attention as a large established tech name, with ongoing interest in how...

If you are wondering whether Bristol-Myers Squibb is attractively priced or already fully valued, the stock's recent moves and current fundamentals give you a lot to weigh up. The share price most recently closed at US$58.08, with returns of 0.7% over 7 days, a 1.7% decline over 30 days, 8.6% year to date and 22.0% over 1 year, while the 3 year and 5 year returns sit at a 5.0% decline and 7.5% respectively. Recent headlines around Bristol-Myers Squibb have continued to focus on its position...

Markel Group (MKL) heads into its 20 May 2026 annual meeting with shareholder proposals on special meeting rights and environmental risk reporting, and a board recommendation that investors vote against both items. See our latest analysis for Markel Group. Those governance debates are landing at a time when Markel Group’s share price has pulled back on a 90 day and year to date basis, even as its 1 year total shareholder return of 10.39% and 3 year total shareholder return of 45.06% reflect a...

Louisiana-Pacific (LPX) shares recently closed at $75.23. The total return over the past 3 months showed an 18.2% decline, and the year-to-date return was 8% lower for investors tracking performance. See our latest analysis for Louisiana-Pacific. Recent share price action has been choppy, with a 7.6% 7 day share price return sitting against a 90 day share price return decline of 18.2% and a weaker 1 year total shareholder return of 11.1%. If Louisiana-Pacific has you reassessing where to find...

If you are wondering whether Capital One Financial at around US$199.84 is a bargain, fully priced, or somewhere in between, the key is to look closely at what different valuation tools are saying. The stock has returned 10.3% over the last week and 11.2% over the last month, while sitting on a 23.9% 1 year return and 115.5% 3 year return, alongside a negative 19.4% year to date move and a 66.3% 5 year return. Recent coverage has focused on Capital One Financial's position as a major US...

Exponent, Inc. has announced a series of leadership changes, including appointing long-time executive Eric Anderson as Chief Financial Officer and promoting Dr. John D. Pye to President, alongside board transitions such as the planned retirement of Dr. Paul R. Johnston and Karen Richardson becoming Chairman. These moves signal a significant internal succession process that elevates leaders with decades of institutional experience in Exponent’s technical, financial, and governance roles,...

Mizuho recently reiterated its positive “Outperform” rating on Arthur J. Gallagher, while institutional investors such as Factory Mutual Insurance Co. reportedly increased their holdings, and the company expanded its Australian footprint by acquiring Brisbane-based International Insurance Brokers Pty Ltd. Together, the analyst endorsement, institutional support, and Australian acquisition highlight how external confidence and geographic expansion could influence Arthur J. Gallagher’s...

CoreCivic Stock Moves After Recent Trading Performance CoreCivic (CXW) has drawn fresh attention after a recent move that leaves the stock at $19.95, with a roughly 10% gain over the past month and a small decline over the past year. See our latest analysis for CoreCivic. That recent 9.6% 1 month share price return sits alongside a 4.9% year to date share price return and a 3 year total shareholder return of about 120%, suggesting momentum has been built over time despite a weaker 1 year...

Johnson & Johnson (JNJ) has opened Q1 2026 with investors focused on how its recent run of earnings ties back to underlying profitability, after reporting Q4 2025 revenue of US$24.6 billion and basic EPS of US$2.10 alongside trailing twelve month EPS of US$11.13 and revenue of US$94.2 billion. Over the last few quarters the company has seen revenue range from US$21.9 billion in Q1 2025 to US$24.6 billion in Q4 2025, while quarterly basic EPS has moved between US$1.41 in Q4 2024 and US$4.57 in...

If you are wondering whether SoFi Technologies at around US$17.91 is priced for opportunity or already reflecting the story, the key is to understand what the current valuation is really saying. The stock has been volatile, with returns of 8.6% over the last 7 days, 1.6% over 30 days, a 34.8% decline year to date, and a 68.0% return over the last year. These moves can shift how the market is pricing both growth potential and risk. Recent headlines have focused on SoFi's position in consumer...

For investors considering whether MercadoLibre at around US$1,840 a share still offers value, or if the best days are already priced in, this article breaks down what the current market price might be implying about the business. The stock has seen short term strength, with returns of 5.6% over the last week and 10.2% over the last 30 days, set against a year to date return of a 6.7% decline and a 13.1% decline over the last year. The 3 year and 5 year returns sit at 39.3% and 20.0%...

Cardinal Health released its 2026 Advanced Therapies Report, focusing on how advanced treatments are shifting toward community-based care. The report outlines how providers are rethinking care delivery models to widen patient access outside traditional hospital settings. Findings add new detail to Cardinal Health's role in advanced therapies beyond its previously covered radiopharmaceutical expansions. For investors watching Cardinal Health (NYSE:CAH), the new report lands at a time when...